Outlook Therapeutics, Inc. Stock price

Equities

OTLK

US69012T3059

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
7.785 USD -5.52% Intraday chart for Outlook Therapeutics, Inc. -0.42% -1.21%
Sales 2024 * 204K Sales 2025 * 11.9M Capitalization 107M
Net income 2024 * -70M Net income 2025 * -62M EV / Sales 2024 * 526 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 9.01 x
P/E ratio 2024 *
-2.11 x
P/E ratio 2025 *
-3.07 x
Employees 24
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.65%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Outlook Therapeutics, Inc.

1 day-5.52%
1 week-1.51%
Current month-10.89%
1 month-13.81%
3 months+1.45%
6 months+80.96%
Current year-1.21%
More quotes
1 week
5.04
Extreme 5.0401
10.72
1 month
5.04
Extreme 5.0401
10.72
Current year
5.04
Extreme 5.0401
10.72
1 year
4.00
Extreme 4.004
40.60
3 years
4.00
Extreme 4.004
65.40
5 years
4.00
Extreme 4.004
176.00
10 years
4.00
Extreme 4.004
878.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 21-07-06
Director of Finance/CFO 58 15-09-14
Chief Tech/Sci/R&D Officer - 23-01-18
Members of the board TitleAgeSince
Chairman 74 18-04-12
Director/Board Member 63 15-12-10
Chief Executive Officer 66 21-07-06
More insiders
Date Price Change Volume
24-03-18 7.785 -5.52% 419,302
24-03-15 8.24 +43.80% 2,273,699
24-03-14 5.73 -11.33% 570,024
24-03-13 6.462 -7.58% 180,019
24-03-12 6.992 -10.57% 219,925

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti- Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
7.785 USD
Average target price
44.33 USD
Spread / Average Target
+469.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Outlook Therapeutics, Inc. - Nasdaq